No. 1Cancer research
Stanford team rewires a lymphoma protein to trigger cancer cell death
Stanford researchers built a two-part molecule, TCIP3, that hijacks BCL6, a protein that helps drive diffuse large B-cell lymphoma. Normally BCL6 silences genes that would let a cell die. TCIP3 ties it to proteins that switch those genes on, so the cell's own self-destruct program runs. In mice carrying human lymphoma tumors, twice-daily doses left the tumors gone by day 11, while untreated tumors remained. The animals showed no obvious toxicity. This is early, animal-only work, published in Cell. The compound needs more refinement and testing in other species before human trials can be considered.
No. 2Public health
Most fathers' deaths after a child's birth in Georgia looked preventable
Northwestern researchers followed the fathers of all 130,267 babies born in Georgia in 2017 through 2022. Of those fathers, 796 died, and about 60% of the deaths were considered preventable. The leading causes were homicide (143), accidental injury (142), suicide (102) and overdose (93). Another 296 deaths were from natural causes. Fathers over 20 also died at lower rates than men who weren't fathers; at ages 30 to 34 it was 120 versus 231 per 100,000. That is an association, and the authors say they don't know why. The study, in JAMA Pediatrics, covers one state. A national version isn't possible yet because national data strips identifying details.
No. 3Vision
Small trial suggests optogenetics can restore some vision in retinitis pigmentosa
A new paper in the New England Journal of Medicine reports that optogenetics may help people with retinitis pigmentosa. This genetic disorder destroys the retina's light-sensing cells, usually causing gradual loss of peripheral and night vision. Many patients are legally blind by young adulthood. Apart from gene therapy for a subset with one specific mutation, there is no cure. Treatment mainly aims to slow the damage. Optogenetics was just recognized with a Nobel Prize. The full article is behind a paywall, so we can't report the trial's size, method or results beyond its headline of some restored vision.
Why it mattersYou learn that a Nobel-recognized technique is being tested against a condition with almost no treatments, though a small trial is only a first step.
Full story at STAT →